NICE: the aggregate is hiding the cohort
Total seats keep rising while the first enterprise cohort renews below plan. The blended number conceals that for roughly two more quarters.
Discussion · 7
I came in sceptical. The distinction between adequate reserves and the earnings path is well made. Curious whether you would still size it the same at a higher entry.
Fair challenge. Invalidation is a close below the lock price on volume, and I should have written that into the card rather than leaving it implicit. (881)
Good to see an invalidation level actually stated. The margin bridge is doing more work here than is acknowledged. Is there a cleaner way to express this than the equity?
Fair challenge. Invalidation is a close below the lock price on volume, and I should have written that into the card rather than leaving it implicit. (886)
I think the setup matters more than the thesis here. Splitting volume from price is what makes this legible. Interested in what the kill switch looks like in practice.
This changed my mind. The lag between intake and revisions is the whole trade. How much of this do you think is already in the buy side's numbers?
This is the second-order point everyone skips. The contract structure matters more than the headline rate. Any view on how the read-across affects the rest of the group?